PURPOSE: Fatigue is a commonly reported symptom by prostate cancer survivors and is associated with significant distress and declines in quality of life. Qigong is a mind-body activity that consists of both physical activity and meditative aspects. This 12-week randomized controlled trial examined the feasibility and efficacy of a Qigong intervention for improving older prostate cancer survivors' levels of fatigue and distress. METHODS:Forty older (median age = 72, range = 58-93), fatigued (cut-off value of ≥ 1 on the CTCAEv4.0, >20 on a fatigue grading scale), and sedentary (<150 min of moderate exercise/week) prostate cancer survivors were randomized to 12 weeks of Qigong or stretching classes. Primary outcomes were feasibility (i.e., retention and class attendance rates) and fatigue [Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)], and secondary outcome was distress [Brief Symptom Inventory-18 (BSI-18)]. RESULTS:Study retention rates did not significantly differ between study groups (Qigong = 80 %, stretching = 65 %, p = 0.48). The Qigong group had significantly higher class attendance than the stretching group (p = 0.04). The Qigong group had significantly greater improvements in the FACIT-Fatigue (p = 0.02) and distress (i.e., BSI-18 Somatization, Anxiety, & Global Severity Index, p's < 0.05), than the Stretching group. CONCLUSIONS: This 12-week Qigong intervention was feasible and potentially efficacious in improving senior prostate cancer survivors' levels of fatigue and distress levels. Future, larger definitive randomized controlled trials are needed to confirm these benefits in older prostate cancer survivors and in racially and ethnically diverse populations. IMPLICATIONS FOR CANCER SURVIVORS: Qigong may be an effective nonpharmacological intervention for the management of senior prostate cancer survivors' fatigue and distress.
RCT Entities:
PURPOSE:Fatigue is a commonly reported symptom by prostate cancer survivors and is associated with significant distress and declines in quality of life. Qigong is a mind-body activity that consists of both physical activity and meditative aspects. This 12-week randomized controlled trial examined the feasibility and efficacy of a Qigong intervention for improving older prostate cancer survivors' levels of fatigue and distress. METHODS: Forty older (median age = 72, range = 58-93), fatigued (cut-off value of ≥ 1 on the CTCAEv4.0, >20 on a fatigue grading scale), and sedentary (<150 min of moderate exercise/week) prostate cancer survivors were randomized to 12 weeks of Qigong or stretching classes. Primary outcomes were feasibility (i.e., retention and class attendance rates) and fatigue [Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)], and secondary outcome was distress [Brief Symptom Inventory-18 (BSI-18)]. RESULTS: Study retention rates did not significantly differ between study groups (Qigong = 80 %, stretching = 65 %, p = 0.48). The Qigong group had significantly higher class attendance than the stretching group (p = 0.04). The Qigong group had significantly greater improvements in the FACIT-Fatigue (p = 0.02) and distress (i.e., BSI-18 Somatization, Anxiety, & Global Severity Index, p's < 0.05), than the Stretching group. CONCLUSIONS: This 12-week Qigong intervention was feasible and potentially efficacious in improving senior prostate cancer survivors' levels of fatigue and distress levels. Future, larger definitive randomized controlled trials are needed to confirm these benefits in older prostate cancer survivors and in racially and ethnically diverse populations. IMPLICATIONS FOR CANCER SURVIVORS: Qigong may be an effective nonpharmacological intervention for the management of senior prostate cancer survivors' fatigue and distress.
Authors: Kathryn H Schmitz; Kerry S Courneya; Charles Matthews; Wendy Demark-Wahnefried; Daniel A Galvão; Bernardine M Pinto; Melinda L Irwin; Kathleen Y Wolin; Roanne J Segal; Alejandro Lucia; Carole M Schneider; Vivian E von Gruenigen; Anna L Schwartz Journal: Med Sci Sports Exerc Date: 2010-07 Impact factor: 5.411
Authors: David C Mohr; Bonnie Spring; Kenneth E Freedland; Victoria Beckner; Patricia Arean; Steven D Hollon; Judith Ockene; Robert Kaplan Journal: Psychother Psychosom Date: 2009-07-11 Impact factor: 17.659
Authors: Rebecca A Campo; Kathleen O'Connor; Kathleen C Light; Yoshio Nakamura; David L Lipschitz; Paul C LaStayo; Lisa Pappas; Kenneth Boucher; Michael R Irwin; Neeraj Agarwal; Anita Y Kinney Journal: Integr Cancer Ther Date: 2013-04-25 Impact factor: 3.279
Authors: G A Curt; W Breitbart; D Cella; J E Groopman; S J Horning; L M Itri; D H Johnson; C Miaskowski; S L Scherr; R K Portenoy; N J Vogelzang Journal: Oncologist Date: 2000
Authors: Karen M Mustian; Lisa K Sprod; Oxana G Palesh; Luke J Peppone; Michelle C Janelsins; Supriya G Mohile; Jennifer Carroll Journal: Curr Sports Med Rep Date: 2009 Nov-Dec Impact factor: 1.733
Authors: Karen M Mustian; Calvin L Cole; Po Ju Lin; Matt Asare; Chunkit Fung; Michelle C Janelsins; Charles S Kamen; Luke J Peppone; Allison Magnuson Journal: Semin Oncol Nurs Date: 2016-10-21 Impact factor: 2.315
Authors: Linda K Larkey; Denise J Roe; Karen L Weihs; Roger Jahnke; Ana Maria Lopez; Carol E Rogers; Byeongsang Oh; Jose Guillen-Rodriguez Journal: Ann Behav Med Date: 2015-04
Authors: Peter M Wayne; M S Lee; J Novakowski; K Osypiuk; J Ligibel; L E Carlson; R Song Journal: J Cancer Surviv Date: 2017-12-08 Impact factor: 4.442
Authors: Michael R Irwin; Richard Olmstead; Carmen Carrillo; Nina Sadeghi; Perry Nicassio; Patricia A Ganz; Julienne E Bower Journal: J Clin Oncol Date: 2017-05-10 Impact factor: 44.544
Authors: Jennifer L McQuade; Sarah Prinsloo; David Z Chang; Amy Spelman; Qi Wei; Karen Basen-Engquist; Carol Harrison; Zonghao Zhang; Debra Kuban; Andrew Lee; Lorenzo Cohen Journal: Psychooncology Date: 2016-09-20 Impact factor: 3.894